Author: s.mengoni@pensiero.it

Home / s.mengoni@pensiero.it
Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal cancer: update on the first real-world study in Germany and Austria – BERING CRC
Articolo

Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal cancer: update on the first real-world study in Germany and Austria – BERING CRC

Prager G, von der Heyde E , Bürkle D, et al. Background: For the therapy of previously treated BRAF V600E-mutant metastatic colorectal cancer, the combination of encorafenib with cetuximab represents a new standard of care. The combination of encorafenib plus cetuximab was approved in the EU in June 2020. The approval was based on positive...

Association of BRAF V600E mutation with survival in patients with metastatic mismatch repair-deficient colorectal cancer
Articolo

Association of BRAF V600E mutation with survival in patients with metastatic mismatch repair-deficient colorectal cancer

Tan E, Whiting J,  Xie H, et al. Background: Colorectal cancer (CRC), while one of the most common cancer diagnoses, can behave heterogeneously based on molecular characteristics. A subset of patients (pts) with CRC are characterized with mismatch repair deficiency (MMR-d), these pts exhibit encouraging responses to immunotherapy. The predictive nature of various factors, such as...

Options beyond BRAF targeted therapy in second-line treatment of patients with BRAFV600E mutant metastatic colorectal cancer
Articolo

Options beyond BRAF targeted therapy in second-line treatment of patients with BRAFV600E mutant metastatic colorectal cancer

Wong V, Hong W,  Ananda S, et al. Background: BRAFmt is a negative prognostic factor in mCRC but also identifies a patient population that may benefit from BRAF targeted therapy. Results from recent trials (BEACON and SWOG1406) demonstrate improved survival outcomes in second- and third-line settings when combining a BRAF inhibitor, an EGFR inhibitor (EGFRi) +/-...

Real-world data analysis of antiangiogenic targeted treatments in second-line following anti-EGFR antibodies and FOLFOX in first-line for patients with metastatic colorectal cancer
Articolo

Real-world data analysis of antiangiogenic targeted treatments in second-line following anti-EGFR antibodies and FOLFOX in first-line for patients with metastatic colorectal cancer

Kagawa Y, Satake H, Shinozaki E, et al. Background: Three antiangiogenic (AA) drugs, bevacizumab (BEV), ramucirumab (RAM) and aflibercept (AFL) are recommended as the second-line (2L) treatment for metastatic colorectal cancer (mCRC) in the CRC treatment guidelines of multiple countries and regions including the US, EU and Japan. However, little evidence of 2L RAM and AFL...

WJOG13219G: Triplet versus doublet in patients with previously untreated BRAFV600E-mutant metastatic colorectal cancer: a multi-institutional real-world data analysis (BRACELET study)
Articolo

WJOG13219G: Triplet versus doublet in patients with previously untreated BRAFV600E-mutant metastatic colorectal cancer: a multi-institutional real-world data analysis (BRACELET study)

Shimozaki K, Hirata K,  Sato T, et al. Background: The survival benefit of FOLFOXIRI plus bevacizumab (Triplet) over Doublet in patients (pts) with BRAFV600E-mutant metastatic colorectal cancer (mCRC) remains controversial. We compared Triplet therapy with Doublet and explored the pts subgroups that could benefit from intensive chemotherapy (chemo) using real-world data. Methods: WJOG13219G was a multicenter, retrospective registry-based...

Encorafenib, cetuximab, and cytotoxic chemotherapy combinations in BRAFV600E CRC murine models
Articolo

Encorafenib, cetuximab, and cytotoxic chemotherapy combinations in BRAFV600E CRC murine models

Woods MN, De Falco V, Claudia Prisco, Background: Based on promising results from latest trials, a crucial point is to evaluate whether encorafenib (E) plus cetuximab (C), alone or in combination with chemotherapy, can improve clinical outcomes relative to current standard of care in previously untreated BRAFV600E mutant mCRC. Considering the high number of BRAFV600E mutant mCRC patients who will never...

Prognostic effect of RAS/BRAF mutations in patients with metastatic colorectal cancer
Articolo

Prognostic effect of RAS/BRAF mutations in patients with metastatic colorectal cancer

Abid H, Szabo A, Taylor BW,  et al. Background: Somatic alterations in KRAS and BRAF have prognostic as well as predictive impact in pts with mCRC; however, the differential impact of various somatic alterations in these genes need further characterization. We analyzed the prognostic impact of specific somatic mutations in KRAS and BRAF in mCRC pts. Methods: We retrospectively reviewed the electronic medical records...

Comprehensive landscape of BRAF variant classes, clonalities, and comutations in metastatic colorectal cancer using ctDNA profiling
Articolo

Comprehensive landscape of BRAF variant classes, clonalities, and comutations in metastatic colorectal cancer using ctDNA profiling

Johnson B, Yang D, Dada HI, et al. Background: Although BRAF V600E accounts for the majority of the BRAF mutations in mCRC, non-V600 BRAF variants have been shown in recent years to represent a distinct molecular subtype of mCRC. This study provides a comprehensive profile of BRAF V600 and non-V600 variants, their clonalities and co-mutations in mCRC using a large genomic database of circulating...

Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer
Articolo

Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer

Morris VK, Christine Megerdichian Parseghian C, Escano M, et al. Background: Encorafenib (E) and cetuximab (C) offers short-lived response and survival benefit for patients (pts) with MSS, BRAFV600E metastatic colorectal cancer (CRC). BRAF + EGFR inhibition induced a transient MSI-H phenotype in preclinical models of MSS, BRAFV600E CRC and may prime these tumors for response to immunotherapy with anti-PD-1 antibodies like...

Safety and efficacy of encorafenib, binimetinib, plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer: Results of a prospective study as an expanded access program
Articolo

Safety and efficacy of encorafenib, binimetinib, plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer: Results of a prospective study as an expanded access program

Takashima A, Kotani D, Kato T, et al. Background: The encorafenib, binimetinib, and cetuximab (triplet) regimen showed survival benefit and a higher response rate over standard chemotherapy among pretreated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) in the phase III BEACON trial. Herein, we report the safety and efficacy of the triplet regimen in...